115 related articles for article (PubMed ID: 38925807)
1. SIRT4 Has an Anti-Cancer Role in Cervical Cancer by Inhibiting Glutamine Metabolism
Zhang Y; Niu X; Wang Y; Bao S; Jiang P; Dong X
Anticancer Res; 2024 Jul; 44(7):2861-2870. PubMed ID: 38925807
[TBL] [Abstract][Full Text] [Related]
2. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.
Jeong SM; Lee A; Lee J; Haigis MC
J Biol Chem; 2014 Feb; 289(7):4135-44. PubMed ID: 24368766
[TBL] [Abstract][Full Text] [Related]
3. The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer.
Jiang W; Ouyang X; Ji Z; Shi W; Wu Y; Yao Q; Wang Y; Yang W; Xiang L; Yang H
Cancer Lett; 2023 Mar; 556():216064. PubMed ID: 36646410
[TBL] [Abstract][Full Text] [Related]
4. SIRT4 functions as a tumor suppressor during prostate cancer by inducing apoptosis and inhibiting glutamine metabolism.
Cai G; Ge Z; Xu Y; Cai L; Sun P; Huang G
Sci Rep; 2022 Jul; 12(1):12208. PubMed ID: 35842463
[TBL] [Abstract][Full Text] [Related]
5. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway.
Ma H; Han F; Yan X; Qi G; Li Y; Li R; Yan S; Yuan C; Song K; Kong B
J Cell Physiol; 2021 Apr; 236(4):2767-2781. PubMed ID: 33184870
[TBL] [Abstract][Full Text] [Related]
6. c-Myc Overexpression Promotes Oral Cancer Cell Proliferation and Migration by Enhancing Glutaminase and Glutamine Synthetase Activity.
Wang T; Cai B; Ding M; Su Z; Liu Y; Shen L
Am J Med Sci; 2019 Sep; 358(3):235-242. PubMed ID: 31324362
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
8. SIRT4 is the molecular switch mediating cellular proliferation in colorectal cancer through GLS mediated activation of AKT/GSK3β/CyclinD1 pathway.
Cui Y; Bai Y; Yang J; Yao Y; Zhang C; Liu C; Shi J; Li Q; Zhang J; Lu X; Zhang Y
Carcinogenesis; 2021 Apr; 42(3):481-492. PubMed ID: 33315089
[TBL] [Abstract][Full Text] [Related]
9. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
10. Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway.
Kim EJ; Juhnn YS
J Biol Chem; 2015 Apr; 290(15):9604-13. PubMed ID: 25713071
[TBL] [Abstract][Full Text] [Related]
11. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
Xing J; Li J; Fu L; Gai J; Guan J; Li Q
Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
13. Loss of SIRT4 promotes the self-renewal of Breast Cancer Stem Cells.
Du L; Liu X; Ren Y; Li J; Li P; Jiao Q; Meng P; Wang F; Wang Y; Wang YS; Wang C
Theranostics; 2020; 10(21):9458-9476. PubMed ID: 32863939
[No Abstract] [Full Text] [Related]
14. Loss of PFKFB4 induces cell cycle arrest and glucose metabolism inhibition by inactivating MEK/ERK/c-Myc pathway in cervical cancer cells.
Wu Y; Zhang L; Bao Y; Wan B; Shu D; Luo T; He Z
J Obstet Gynaecol; 2022 Aug; 42(6):2399-2405. PubMed ID: 35659173
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of SIRT4 Expression Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma.
Nakahara Y; Yamasaki M; Sawada G; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mimori K; Mori M; Doki Y
Oncology; 2016; 90(6):347-55. PubMed ID: 27082627
[TBL] [Abstract][Full Text] [Related]
16. SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway.
Fu L; Dong Q; He J; Wang X; Xing J; Wang E; Qiu X; Li Q
Oncogene; 2017 May; 36(19):2724-2736. PubMed ID: 27941873
[TBL] [Abstract][Full Text] [Related]
17. Circ_0001093 promotes glutamine metabolism and cancer progression of esophageal squamous cell carcinoma by targeting miR-579-3p/glutaminase axis.
Qian CJ; Tong YY; Wang YC; Teng XS; Yao J
J Bioenerg Biomembr; 2022 Apr; 54(2):119-134. PubMed ID: 35322289
[TBL] [Abstract][Full Text] [Related]
18. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice.
Wang YS; Du L; Liang X; Meng P; Bi L; Wang YL; Wang C; Tang B
Hepatology; 2019 Apr; 69(4):1614-1631. PubMed ID: 30552782
[TBL] [Abstract][Full Text] [Related]
19. VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1α/HO-1 pathway.
Tong Y; Kai J; Wang S; Yu Y; Xie S; Zheng H; Wang Y; Liu Y; Zhu K; Guan X; Guo L; Lu R
Cell Death Dis; 2021 Jun; 12(7):621. PubMed ID: 34135317
[TBL] [Abstract][Full Text] [Related]
20. Exogenous interleukin-1 beta promotes the proliferation and migration of HeLa cells via the MEK/ERK signaling pathway.
Zhang J; Wang L; Liu Y; Liu W; Ma Z
Mol Biol Rep; 2022 May; 49(5):3765-3772. PubMed ID: 35301650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
